Ask AI
ProCE Banner Activity

Systemic Therapy Beyond HER2-Positive Disease and Multidisciplinary CNS Management

Slideset

Explore systemic therapy and CNS management of breast cancer brain metastases beyond HER2-positive disease, including evidence for antibody–drug conjugates (ADCs) in metastatic triple-negative and HR-positive/HER2-negative breast cancer. Review ADC-associated adverse event management, ongoing clinical trials, and the role of brain MRI in evaluating suspected progression and treatment-related changes.

Released: November 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This educational activity is intended for neuro-oncologists, oncologists, and other multidisciplinary healthcare professionals involved in the care of individuals with breast cancer brain metastases.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply intracranial efficacy and safety data from clinical trials of antibody-drug conjugates and other CNS-active systemic therapies to select and sequence treatment for patients with breast cancer brain metastases

  • Determine the appropriate use of brain MRI to evaluate suspected brain metastases, assess CNS progression, and distinguish disease progression from treatment-related changes and other neurologic complications

  • Recall ongoing and emerging clinical trials evaluating novel ADC-based and other CNS-directed treatment strategies, and counsel appropriate patients with breast cancer regarding clinical trial participation

Additional Information

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.